Entities / Company
Atara Biotherapeutics, Inc..
clinical-stage biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 21
What's happening
Gone quiet
No new reports in 90+ days-
Atara Biotherapeutics, Inc. develops therapies for patients in the US and UK, coinciding with the pledge to unleash American oil and gas.Some support1 report
-
Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.Some support1 report
-
The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.Some support1 report
-
FDA accepted the BLA filing for Tab-cel from Atara Biotherapeutics on July 24, 2025.Some support1 report
-
The FDA accepted the resubmitted Biologics License Application (BLA) from Atara Biotherapeutics, Inc. on September 4, 2025. Greg Ciongoli also assumed the role of Board Chair.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Atara Biotherapeutics, Inc. this week
News at the entities that move Atara Biotherapeutics, Inc. most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Atara Biotherapeutics, Inc.
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Atara Biotherapeutics, Inc.
-
Freedom Capital Mentioned togetherRating upgrades and restatements on ASML shares, including an upgrade from hold to strong-buy, were announced.Moves Atara Biotherapeutics, Inc.
Connections
The 3 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Atara Biotherapeutics is subject to the formal regulatory oversight and disclosure requirements of the SEC.
-
FDA Structural
The FDA formally regulates Atara Biotherapeutics, overseeing clinical trials, granting approvals, and accepting BLA filings.
-
Freedom Capital Mentioned together
Atara Biotherapeutics' stock rating was upgraded, indicating market interest.
History
Events by the month they beganJune 2026
5 events- Atara Biotherapeutics, Inc. develops therapies for patients in the US and UK, coinciding with the pledge to unleash American oil and gas.
- Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.
- The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.
- FDA accepted the BLA filing for Tab-cel from Atara Biotherapeutics on July 24, 2025.
- The FDA accepted the resubmitted Biologics License Application (BLA) from Atara Biotherapeutics, Inc. on September 4, 2025. Greg Ciongoli also assumed the role of Board Chair.